SQZ Biotechnologies Revenue and Competitors

Claim your profile

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • SQZ Biotechnologies's estimated annual revenue is currently $17.2M per year.(i)
  • SQZ Biotechnologies received $72.0M in venture funding in August 2018.
  • SQZ Biotechnologies's estimated revenue per employee is $246,143
  • SQZ Biotechnologies's total funding is $226.4M.
  • SQZ Biotechnologies's current valuation is $228.7M. (January 2022)

Employee Data

  • SQZ Biotechnologies has 70 Employees.(i)
  • SQZ Biotechnologies grew their employee count by -50% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

SQZ Biotech is a unique cell therapy company, utilizing the proprietary CellSqueeze® platform to develop a new generation of cell therapies. SQZ currently focuses on the development of novel treatments that leverage targeted immune modulation to impact oncology and autoimmune diseases. SQZ: Empower cells to change lives.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





SQZ Biotechnologies News

2022-04-20 - SQZ Biotechnologies Receives FDA Fast Track Designation ...

SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients...

2022-04-20 - SQZ Biotechnologies (SQZ) Granted FDA Fast Track ...

SQZ Biotechnologies (NYSE: SQZ) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the...

2022-04-20 - $SQZ SQZ Biotechnologies Receives FDA Fast Track ...

SQZ Biotechnologies Receives FDA Fast Track Designation For Its Lead Cell Therapy Candidate For The Treatment Of HPV16+ Tumors.

2021-09-13 - SQZ BIOTECHNOLOGIES CO : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD Disclosure. On September 13, 2021, SQZ Biotechnologies Company (the "Company") issued a press release titled "SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform." A copy of the press release is attached hereto ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

SQZ Biotechnologies Funding

DateAmountRoundLead InvestorsReference
2015-06-25$5.0MAPolaris PartnersArticle
2016-12-05$4.0MBQuark Venture IncArticle
2017-12-06$UndisclosedUndisclosedJDRF T1D Fund.Article